Because You Care About Your Patients With ROS1+ NSCLC: Recent Revolutions in Treatment - a podcast by ReachMD

CME credits: 0.50

Valid until: 29-03-2021

Claim your CME credit at https://reachmd.com/programs/cme/because-you-care-about-your-patients-with-ros1-nsclc-recent-revolutions-in-treatment/11292/

The discovery of predictive biomarkers, including ROS1 rearrangements, has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. First-line therapy options for ROS1 rearrangement–positive metastatic NSCLC now include crizotinib, entrectinib, and ceritinib, with the NCCN recommending crizotinib and entrectinib as preferred agents. Additional agents are being studied to improve treatment outcomes of patients with ROS1 rearrangement–positive NSCLC that becomes resistant to available therapies.

This activity reviews the most recent clinical data and evidence-based updates and provides expert insights on the treatment of ROS1+ metastatic NSCLC.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD